Astrana Health (NASDAQ:ASTH) Issues FY 2024 Earnings Guidance

by · The Cerbat Gem

Astrana Health (NASDAQ:ASTH – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 1.060-1.190 for the period, compared to the consensus EPS estimate of 1.310. The company issued revenue guidance of $2.0 billion-$2.0 billion, compared to the consensus revenue estimate of $1.8 billion. Astrana Health also updated its FY24 guidance to $1.06-1.19 EPS.

Astrana Health Stock Performance

Shares of NASDAQ ASTH traded down $12.12 during trading hours on Friday, reaching $46.96. 796,465 shares of the stock were exchanged, compared to its average volume of 223,937. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of 32.61, a P/E/G ratio of 2.27 and a beta of 1.24. The stock’s fifty day simple moving average is $55.51 and its 200 day simple moving average is $47.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.84 and a current ratio of 1.84. Astrana Health has a 52 week low of $29.63 and a 52 week high of $63.20.

Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.01. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The firm had revenue of $486.30 million for the quarter, compared to analysts’ expectations of $440.68 million. During the same quarter last year, the business earned $0.28 EPS. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. Sell-side analysts predict that Astrana Health will post 1.31 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th. BTIG Research boosted their price target on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. TD Cowen started coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price objective on the stock. Stifel Nicolaus increased their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, KeyCorp assumed coverage on Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $62.00.

Read Our Latest Report on ASTH

Astrana Health Company Profile

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

Featured Stories